For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
The first time you fall down a rabbit hole of COVID-19 pseudoscience
The first time you fall down a rabbit hole of COVID-19 pseudoscience

GP Jo Scott-Jones uses Alice’s Adventures in Wonderland to help illustrate the COVID-19 fantasy world created by some physicians, then suggests how you can avoid falling into it
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
1. Roser M, Ritchie H, Ortiz-Ospina E, et al. Coronavirus Pandemic (COVID-19). May 2021. ourworldindata.org/coronavirus
2. US Food and Drug Administration. Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of Casirivimab and Imdevimab. 2020. www.fda.gov/media/143892/download
3. US Food and Drug Administration. Frequently Asked Questions on the Emergency Use Authorization for Bamlanivimab and Etesevimab. May 2021. www.fda.gov/media/145808/download